使用胆固醇基普鲁兰多糖（CHP）-NY-ESO-1和CHP-HER2与OK-432联合疫苗接种的患者针对NY-ESO-1和HER2抗原的抗体反应。
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
作者信息
Aoki Masatoshi, Ueda Shugo, Nishikawa Hiroyoshi, Kitano Shigehisa, Hirayama Michiko, Ikeda Hiroaki, Toyoda Hideki, Tanaka Kyosuke, Kanai Michiyuki, Takabayashi Arimichi, Imai Hiroshi, Shiraishi Taizo, Sato Eiichi, Wada Hisashi, Nakayama Eiichi, Takei Yoshiyuki, Katayama Naoyuki, Shiku Hiroshi, Kageyama Shinichi
机构信息
Department of Haematology and Oncology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie 514-8507, Japan.
出版信息
Vaccine. 2009 Nov 16;27(49):6854-61. doi: 10.1016/j.vaccine.2009.09.018. Epub 2009 Sep 15.
Combination vaccines of the NY-ESO-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible.
将与胆固醇接枝普鲁兰（CHP）复合的NY-ESO-1蛋白（CHP-NY-ESO-1）以及截短的146HER2蛋白与CHP（CHP-HER2）组成的联合疫苗，与免疫佐剂OK-432一起皮下注射给8名食管癌患者。疫苗接种耐受性良好。使用患者血清以及先前单一CHP-NY-ESO-1或CHP-HER2疫苗试验的样本，分析了NY-ESO-1和HER2特异性抗体反应。联合疫苗研究中对NY-ESO-1的反应与单一疫苗相当。对于HER2的反应，联合疫苗中的抗体反应较少。尽管对NY-ESO-1和HER2抗原的抗体反应存在明显的个体差异，但每个患者体内对这些抗原的反应模式具有可比性。针对OK-432的抗体未增加。靶向多种抗原的蛋白癌症疫苗是可行的。
Zotero 插件